<code id='A08D11A163'></code><style id='A08D11A163'></style>
    • <acronym id='A08D11A163'></acronym>
      <center id='A08D11A163'><center id='A08D11A163'><tfoot id='A08D11A163'></tfoot></center><abbr id='A08D11A163'><dir id='A08D11A163'><tfoot id='A08D11A163'></tfoot><noframes id='A08D11A163'>

    • <optgroup id='A08D11A163'><strike id='A08D11A163'><sup id='A08D11A163'></sup></strike><code id='A08D11A163'></code></optgroup>
        1. <b id='A08D11A163'><label id='A08D11A163'><select id='A08D11A163'><dt id='A08D11A163'><span id='A08D11A163'></span></dt></select></label></b><u id='A08D11A163'></u>
          <i id='A08D11A163'><strike id='A08D11A163'><tt id='A08D11A163'><pre id='A08D11A163'></pre></tt></strike></i>

          focus

          focus

          author:Wikipedia    Page View:34
          Photo illustration based on photograph of The University of Texas MD Anderson Cancer Center in Houston, Texas in 2022
          Photo illustration: STAT; Photo: Adobe

          Prominent immunologist and oncologist Padmanee Sharma defended herself in court on Friday against a lawsuit that alleges she threatened to undermine a junior faculty member’s career, made defamatory comments about the younger scientist, and attempted to take credit for work that she didn’t do.

          In legal filings submitted to the Harris County District Court, Sharma said that she made substantial contributions to an immunotherapy project that were ignored, and that a third-party assessment commissioned by MD Anderson Cancer Center concluded Sharma should be given credit for her role. Sharma had previously issued a general denial of the allegations against her and claimed immunity from the suit as a government employee. As part of the University of Texas, MD Anderson is a state institution.

          advertisement

          The filing, which was submitted by Texas Attorney General Ken Paxton and lawyers in his office, also argued that the junior researcher’s lawsuit should be made against MD Anderson, not Sharma, and asked the court to dismiss the suit if it is not amended within 30 days. “Dr. Sharma is not a proper party to this lawsuit; only MDACC is,” the filing states. “This lawsuit is about proper accreditation in scientific literature for research performed at MDACC by MDACC faculty.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          AstraZeneca CEO says participant had neurological symptoms, could be discharged today
          AstraZeneca CEO says participant had neurological symptoms, could be discharged today

          PascalSoriot,thechiefexecutiveofficerofAstraZeneca.WinMcNamee/GettyImagesTheparticipantwhotriggereda

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          What we’ve learned from the Aduhelm mess

          MollyFergusonforSTATSTATnowpublishesselectedLetterstotheEditorreceivedinresponsetoFirstOpinionessays